因塞特医疗 INCY 深 沪
等待开盘 02-07 09:30:00 美东时间
108.44
+5.680
+5.53%
华盛通- 最 高112.29
- 今 开103.75
- 成交量 188.33万股
- 最 低 97.63
- 昨 收 102.76
- 总市值 2407.37万
- 52周最高 112.29
- 市盈率 静 25.39
- 换手率 848.34%
- 52周最低 0.00
- 委 比 -28.87%
- 总股本 0.00亿
- 历史最高 112.29
- 量 比 1.21
- 振 幅 14.27%
- 历史最低 0.00
- 每 手 1
- 风险率 15.85%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Tempus AI Stock Soars After Posting Triple-Digit Diagnostics Growth
Tempus AI (NASDAQ: TEM) stock rose after releasing preliminary Q4 and 2025 results, with revenue of $1.27B in 2025 and $367M in Q4.
01-12 18:47
Incyte Study Shows Lymphoma Drug Combo Slows Aggressive Blood Cancer
Incyte reported positive results from a trial of tafasitamab as a first-line treatment for adults with DLBCL. No new safety issues were seen.
01-06 00:59
Incyte Delivers Robust Growth, But 2028 Patent Expiry Still Looms
Incyte Q3 revenue rose 20% to $1.37 billion, topping estimates, as Jakafi and Niktimvo fueled growth and the company raised its 2025 revenue outlook.
2025-10-29 02:44
Earnings Scheduled For October 28, 2025
Companies Reporting Before The Bell • PayPal Holdings (NASDAQ:PYPL) is expected...
2025-10-28 19:11
Incyte Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
In the preceding three months, 6 analysts have released ratings for Incyte (NAS...
2025-03-11 22:00
JMP Securities Reiterates Market Perform on Incyte
JMP Securities analyst Reni Benjamin reiterates Incyte (NASDAQ:INCY) with a Market Perform.
2024-09-18 00:22
Guggenheim Maintains Buy on Incyte, Raises Price Target to $92
Guggenheim analyst Michael Schmidt maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $86 to $92.
2024-09-17 00:45
Reported Saturday, Incyte Unveils Results For CDK2 Inhibitor INCB123667 In Advanced Solid Tumors, Ovarian Cancer Among Highlighted
New antitumor response data from a range of doses and regimens unveiled today at Incyte investor event These results build upon safety and tolerability data presented earlier today during a mini-oral presentation at
2024-09-16 15:58
Cantor Fitzgerald Reiterates Neutral on Incyte
Cantor Fitzgerald analyst Eric Schmidt reiterates Incyte (NASDAQ:INCY) with a Neutral.
2024-09-10 01:09
礼来与埃及友商签署授权协议 扩大斑秃药物Olumiant在非洲供应
智通财经获悉，礼来公司(LLY.US)周三宣布与埃及制药公司EVA Pharma宣布建立合作伙伴关系，到2030年，将向非洲49个中低收入国家的人们提供JAK抑制剂Olumiant (baricitinib)，这是一种被批准用于治疗类风湿性关节炎、斑秃、特应性皮炎和新型冠状病毒肺炎的药物。 交易完成后，EVA Pharma将在非洲49个中低收入国家生产和供应baricitinib，服务于约2万人。该公司在当地生产的baricitinib将于2026年开始销售。baricitinib是礼来公司和因赛特(INCY.US)合作开发的一款药物，适用于类风湿性关节炎、特应性皮炎等疾病。 该协议被确定为一...
2024-09-04 21:15
